Genitourinary Cancers Clinical Trials & Research at Providence Medical Group

Genitourinary (GU) cancers encompass a diverse group of malignancies affecting the urinary system and the male reproductive organs. This category includes cancers of the bladder, kidneys, prostate, testicles, and penis. These cancers vary widely in their biology, prognosis, and treatment options, making clinical research crucial for improving patient outcomes.

Clinical trials are fundamental to the advancement of GU cancer treatment. These studies investigate new therapies and interventions, aiming to enhance the effectiveness and reduce the side effects of existing treatments. They encompass a wide range of approaches, including novel drug therapies, immunotherapies, targeted treatments, surgical techniques, and combinations of these modalities.

Prostate/Endometrial and Pancreatic cancer studies are also included in these trials.

Pancreatic cancer develops in the pancreatic ductal, acinar, and islet cells. Most pancreatic cancers are adenocarcinoma of pancreatic ductal (PDA) origin. Pancreatic cancer accounts for about 3 percent of all cancers in the U.S. Risk factors that can be changed include tobacco use, obesity, and workplace exposure to certain chemicals.

Providence Medical Group is currently enrolling patients for the following genitourinary cancers clinical trials: